Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS

Peter A. Calabresi; N. S. Fields; H. W. Maloni; A. Hanham; J. Carlino; J. Moore; M. C. Levin; S. Dhib-Jalbut; L. R. Tranquill; H. Austin; Henry F. McFarland; M. K. Racke

doi:10.1212/WNL.51.1.289

Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS

Peter A. Calabresi, N. S. Fields, H. W. Maloni, A. Hanham, J. Carlino, J. Moore, M. C. Levin, S. Dhib-Jalbut, L. R. Tranquill, H. Austin, Henry F. McFarland, M. K. Racke

Research output: Contribution to journal › Article › peer-review

109 Scopus citations

Abstract

Transforming growth factor (TGF)-β2 is a pleiotropic cytokine associated with remissions in multiple sclerosis (MS) and amelioration of allergic encephalomyelitis. We assessed the safety of TGF-β2 in an open- label trial of 11 patients with secondary progressive (SP) MS. Five patients had a reversible decline in the glomerular filtration rate. There was no change in expanded disability status scale or MRI lesions during treatment. Systemic TGF-β2 may be associated with reversible nephrotoxicity, and further investigation of its therapeutic potential in MS should be performed with caution.

Original language	English (US)
Pages (from-to)	289-292
Number of pages	4
Journal	Neurology
Volume	51
Issue number	1
DOIs	https://doi.org/10.1212/WNL.51.1.289
State	Published - Jul 1998
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.51.1.289

Cite this

@article{0a616366927e46858fd215ecfe51180b,

title = "Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS",

abstract = "Transforming growth factor (TGF)-β2 is a pleiotropic cytokine associated with remissions in multiple sclerosis (MS) and amelioration of allergic encephalomyelitis. We assessed the safety of TGF-β2 in an open- label trial of 11 patients with secondary progressive (SP) MS. Five patients had a reversible decline in the glomerular filtration rate. There was no change in expanded disability status scale or MRI lesions during treatment. Systemic TGF-β2 may be associated with reversible nephrotoxicity, and further investigation of its therapeutic potential in MS should be performed with caution.",

author = "Calabresi, {Peter A.} and Fields, {N. S.} and Maloni, {H. W.} and A. Hanham and J. Carlino and J. Moore and Levin, {M. C.} and S. Dhib-Jalbut and Tranquill, {L. R.} and H. Austin and McFarland, {Henry F.} and Racke, {M. K.}",

year = "1998",

month = jul,

doi = "10.1212/WNL.51.1.289",

language = "English (US)",

volume = "51",

pages = "289--292",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS

AU - Calabresi, Peter A.

AU - Fields, N. S.

AU - Maloni, H. W.

AU - Hanham, A.

AU - Carlino, J.

AU - Moore, J.

AU - Levin, M. C.

AU - Dhib-Jalbut, S.

AU - Tranquill, L. R.

AU - Austin, H.

AU - McFarland, Henry F.

AU - Racke, M. K.

PY - 1998/7

Y1 - 1998/7

N2 - Transforming growth factor (TGF)-β2 is a pleiotropic cytokine associated with remissions in multiple sclerosis (MS) and amelioration of allergic encephalomyelitis. We assessed the safety of TGF-β2 in an open- label trial of 11 patients with secondary progressive (SP) MS. Five patients had a reversible decline in the glomerular filtration rate. There was no change in expanded disability status scale or MRI lesions during treatment. Systemic TGF-β2 may be associated with reversible nephrotoxicity, and further investigation of its therapeutic potential in MS should be performed with caution.

AB - Transforming growth factor (TGF)-β2 is a pleiotropic cytokine associated with remissions in multiple sclerosis (MS) and amelioration of allergic encephalomyelitis. We assessed the safety of TGF-β2 in an open- label trial of 11 patients with secondary progressive (SP) MS. Five patients had a reversible decline in the glomerular filtration rate. There was no change in expanded disability status scale or MRI lesions during treatment. Systemic TGF-β2 may be associated with reversible nephrotoxicity, and further investigation of its therapeutic potential in MS should be performed with caution.

UR - http://www.scopus.com/inward/record.url?scp=0031866885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031866885&partnerID=8YFLogxK

U2 - 10.1212/WNL.51.1.289

DO - 10.1212/WNL.51.1.289

M3 - Article

C2 - 9674825

AN - SCOPUS:0031866885

SN - 0028-3878

VL - 51

SP - 289

EP - 292

JO - Neurology

JF - Neurology

IS - 1

ER -

Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this